Is the effect worth the risk? - The most common complaints during oral isotretinoin anti-acne therapy and controversies around its adverse effects
Keywordsacne, isotretinoin, adverse effects, depression
Introduction and purpose: Acne vulgaris, the most common skin disease, causes medical, esthetic and psychosocial problems. Isotretinoin, the vitamin A-derivative, has been the most effective treatment for acne vulgaris. It provides significant improvement and long-term remission. However, it leads to multiple side effects. The aim of our study was to evaluate the prevalence of adverse effects in patients treated with isotretinoin and analyze the most commonly reported symptoms.
Material and methods: The study was conducted using original survey questionnaire addressed to members of Polish group of patients treated with isotretinoin. 196 responds were collected and confronted with current PubMed publications.
Results: The most common mucocutaneous side effects, such as dry lip, dryness of the mucous membranes, xerodermia and dryness of the conjunctiva occurred in 92,6%, 73,5%, 66,8% and 66,3% of respondents, respectively. Both, tiredness and back pain were reported by 70,4% of respondents; myalgia - 55,1%, arthalgia - 32,1% and stiffness of joints - 26,0%. Mood change occurred in 54,6%, hair loss in 50,0%, gastrointestinal symptoms, such as abdominal pain and diarrhea – in 15,8% and 10,7%.
Conclusions: All of the most common isotretinoin side effects are usually mild and dose-dependent. However, their prevalence is very high. Isotretinoin’s association to depression and suicidality remains unclear. In spite of the previous data, the risk of inflammatory bowel disease is probably not increased in patients isotretinoin exposed. However, more studies are necessary.
Gebauer K. Acne in adolescents. Aust Fam Physician. 2017;46:892–5.
Wolkenstein P, Machovcová A, Szepietowski JC, Tennstedt D, Veraldi S, Delarue A. Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries. J Eur Acad Dermatol Venereol JEADV. 2018;32:298–306.
Katsambas AD, Stefanaki C, Cunliffe WJ. Guidelines for treating acne. Clin Dermatol. 2004;22:439–44.
Barnes LE, Levender MM, Fleischer AB, Feldman SR. Quality of life measures for acne patients. Dermatol Clin. 2012;30:293–300, ix.
Tan J, Boyal S, Desai K, Knezevic S. Oral Isotretinoin. Dermatol Clin. 2016;34:175–84.
Layton A. The use of isotretinoin in acne. Dermatoendocrinol. Taylor & Francis; 2009;1:162–9.
Borghi A, Mantovani L, Minghetti S, Giari S, Virgili A, Bettoli V. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol JEADV. 2011;25:1094–8.
Tan TH, Hallett R, Yesudian PD. Efficacy and relapse rates of different Isotretinoin dosages in treating acne vulgaris: systemic review. Clin Med. Royal College of Physicians; 2016;16:s34.
Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017;30:e12483.
Karadag AS, Aksoy B, Parish LC. Retinoids in Dermatology. CRC Press; 2019.
Tasdelen OY, Yurdakul FG, Duran S, Bodur H. Isotretinoin-induced arthritis mimicking both rheumatoid arthritis and axial spondyloarthritis. Int J Rheum Dis. 2015;18:466–9.
Yıldızgören MT, Rifaioğlu EN, Demirkapı M, Ekiz T, Micooğulları A, Şen T, et al. Isotretinoin treatment in patients with acne vulgaris: does it impact muscle strength, fatigue, and endurance? Cutis. 2015;96:33–6.
Drozd M, Czarnota J, Dobrzyński M, Skubel T, Sokół D, Dudek I, et al. Impact of oral isotretinoin therapy on musculoskeletal system and physical activity in patients with acne. J Educ Health Sport. 2020;10:372–82.
Li C, Chen J, Wang W, Ai M, Zhang Q, Kuang L. Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis. BMJ Open [Internet]. 2019 [cited 2020 Jul 22];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347928/
Melnik BC. Apoptosis May Explain the Pharmacological Mode of Action and Adverse Effects of Isotretinoin, Including Teratogenicity. Acta Derm Venereol. 2017;97:173–81.
Huang Y-C, Cheng Y-C. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;76:1068-1076.e9.
İslamoğlu ZGK, Altınyazar HC. Effects of isotretinoin on the hair cycle. J Cosmet Dermatol. 2019;18:647–51.
Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178:76–85.
Wright S, Strunk A, Garg A. Risk of new onset inflammatory bowel disease among acne vulgaris patients exposed to isotretinoin. J Am Acad Dermatol. 2020;
Chroni E, Monastirli A, Tsambaos D. Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf. 2010;33:25–34.
Crijns HJMJ, Straus SM, Gispen-de Wied C, de Jong-van den Berg LTW. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol. 2011;164:238–44.
How to Cite
LicenseThe periodical offers access to content in the Open Access system under the Creative Commons non-exclusive license (CC BY-ND 4.0).
Number of views and downloads: 5
Number of citations: 0